ASCO GI 2021 | Regorafenib plus pembrolizumab for first-line treatment of advanced HCC

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents the results of an ongoing Phase Ib study of regorafenib 80 mg/day plus pembrolizumab for first-line treatment of advanced hepatocellular carcinoma (HCC). The combination of regorafenib plus pembrolizumab for first-line advanced HCC demonstrated promising anti-tumor activity with an acceptable safety profile and warrants further evaluation in this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).